Integra LifeSciences Holdings Corporation
IART
$23.95
$1.345.93%
| Weiss Ratings | IART - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | D+ | |||
| Rating Factors | IART - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Fair | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | IART - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.53 | |||
| Price History | IART - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 3.19% | |||
| 30-Day Total Return | -9.18% | |||
| 60-Day Total Return | -0.25% | |||
| 90-Day Total Return | 23.96% | |||
| Year to Date Total Return | 4.04% | |||
| 1-Year Total Return | -33.88% | |||
| 2-Year Total Return | -54.48% | |||
| 3-Year Total Return | -63.22% | |||
| 5-Year Total Return | -48.03% | |||
| 52-Week High % Change | -38.51% | |||
| 52-Week Low % Change | 34.54% | |||
| Price | IART - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $36.77 | |||
| 52-Week Low Price | $16.81 | |||
| 52-Week Low Price (Date) | Oct 03, 2024 | |||
| 52-Week High Price (Date) | Mar 11, 2024 | |||
| Valuation | IART - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 1.75B | |||
| Enterprise Value | 3.46B | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.09 | |||
| Earnings Per Share Growth | -110.77% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 1.07 | |||
| Price/Book (Q) | 1.13 | |||
| Enterprise Value/Revenue (TTM) | 2.15 | |||
| Price | $23.95 | |||
| Enterprise Value/EBITDA (TTM) | 10.88 | |||
| Enterprise Value/EBIT | 19.53 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | IART - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 76.42M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | IART - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 609 275 0500 | |||
| Address | 1100 Campus Road Princeton, NJ 08540 | |||
| Website | www.integralife.com | |||
| Country | United States | |||
| Year Founded | 1989 | |||
| Profitability | IART - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 10.99% | |||
| Profit Margin | -0.43% | |||
| Management Effectiveness | IART - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 2.83% | |||
| Return on Equity | -- | |||
| Income Statement | IART - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 1.61B | |||
| Total Revenue (TTM) | 1.61B | |||
| Revenue Per Share | $21.07 | |||
| Gross Profit (TTM) | 954.52M | |||
| EBITDA (TTM) | 318.02M | |||
| EBIT (TTM) | 177.12M | |||
| Net Income (TTM) | -6.94M | |||
| Net Income Avl. to Common (TTM) | -6.94M | |||
| Total Revenue Growth (Q YOY) | 11.49% | |||
| Earnings Growth (Q YOY) | -2.01% | |||
| EPS Diluted (TTM) | -0.09 | |||
| EPS Diluted Growth (Q YOY) | 0.40% | |||
| Balance Sheet | IART - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 273.57M | |||
| Cash Per Share (Q) | $3.58 | |||
| Total Current Assets (Q) | 1.08B | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 1.55B | |||
| Current Ratio (Q) | 1.173 | |||
| Book Value Per Share (Q) | $20.03 | |||
| Total Assets (Q) | 4.04B | |||
| Total Current Liabilities (Q) | 922.13M | |||
| Total Debt (Q) | 1.99B | |||
| Total Liabilities (Q) | 2.49B | |||
| Total Common Equity (Q) | 1.55B | |||
| Cash Flow | IART - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -390.81M | |||
| Cash from Financing (TTM) | 237.86M | |||
| Net Change in Cash (TTM) | -30.03M | |||
| Levered Free Cash Flow (TTM) | 75.49M | |||
| Cash from Operations (TTM) | 129.38M | |||
